Unlearn.AI

?? #ADPD2025 in Vienna is around the corner, and we’re excited to showcase two key contributions: ?? Presentation with AbbVie: “Applications of Digital Twins of Alzheimer’s Disease Participants for Designing Efficient Trials and Improving Confidence in Decision-Making” ?? Poster Presentation: “Machine Learning Model Enables Accelerated Enrollment Timelines in Parkinson’s Disease Clinical Trials” Connect with us to learn how we’re partnering with pharma and biotech companies to design and optimize #clinicaltrials using AI-powered #digitaltwins — making #clinicaldevelopment faster, smarter, and more reliable. ——— AD/PD - Advances in Science & Therapy; Steven Herne; Andrew Stelzer; Cary M.; Aaron Smith; Luis Olmos, PhD, MBA; Tricia Sorrentino; Martin Koch; Alyssa Vanderbeek

#UnlearnerSpotlight ?? Izelle Javellana Role: “I'm the People & Culture Manager at Unlearn. I oversee the employee experience from onboarding to workplace to company onsites—ensuring Unlearners are engaged, equipped, and excited to do their best work!” Favorite part about working at Unlearn: “The people, of course! Everyone here is not only brilliant and passionate about the mission, but they're good people—you know, the people you'd be friends with, laugh with, and learn from even if you didn't work together!”

?? We were thrilled to partner with Women In Data?? to host our event, “Revolutionizing Healthcare with AI,” at our San Francisco headquarters last week. With nearly 100 attendees, we brought together an incredible group of industry leaders, data scientists, and healthcare professionals for a thought-provoking and inspiring discussion to explore the opportunities, challenges, and ethical considerations of integrating #AI into #healthcare. A special thank you to Rachel Mak-McCully, PhD, Aaron Smith, Alyssa Vanderbeek, Holly Uber, Kimiko Mitchell, Nadine Besson, Svetlana Kazantseva, Swagata Ashwani, Natasha Lalwani, and the entire Women in Data team for their contributions to the success of this event.

Last week, our Senior Director of Clinical Affairs, Luis Olmos, PhD, MBA, was invited to present at the Digital Innovations in Clinical Trials conference in Berlin. His presentation, "Enhancing Clinical Trials with Digital Twins: Improving Design, Decision-Making, and Enrollment Speed," offered valuable insights into how #digitaltwins are transforming the #clinicaltrial landscape. ?? ——— TBM Group

?? We were thrilled to showcase our work at AD/PD Boston through two key contributions—our presentation, “Use of digital twins in a Phase 2a trial to predict disease progression of participants with mild-to-moderate Alzheimer’s supports early signals of efficacy,” in collaboration with remynd, and our poster, “Enhancing Clinical Trial Inclusivity in AD with Digital Twins Generator.” ?? ——— Martin Koch; Anurag Kulkarni; Yujia(Susanna) Qiao

"The long-term potential of digital twins lies in their ability to predict individual health outcomes with higher precision. If accurate, these models could reduce the guesswork and trial-and-error inherent in clinical development, leading to more precise treatments." ?? Our founder and Machine Learning Scientist, Aaron Smith, had his article, "The promise of digital twins in healthcare," featured in Drug Target Review's March AI report. Read it here: https://lnkd.in/gAkV5KTK

We’re excited to attend AD/PD - Advances in Science & Therapy 2025 in Vienna in a couple of weeks! Don’t miss our presentation, “Applications of Digital Twins of Alzheimer’s Disease Participants for Designing Efficient Trials and Improving Confidence in Decision-Making,” in collaboration with AbbVie, and our poster, “Machine Learning Model Enables Accelerated Enrollment Timelines in Parkinson’s Disease Clinical Trials.” Connect with our team to learn how our AI-powered solutions are revolutionizing clinical trials by optimizing trial design, enhancing power, simulating outcomes, and more—delivering faster results, reducing millions in costs, and accelerating life-saving therapies to patients. ??

The Alzheimer's & Parkinson's drug development summit kicks off in Boston today. Unlearn.AI will be presenting encouraging results from our collaboration on the use of ?????????????? ?????????? to predict disease progression in a Phase 2a trial for mild-to-moderate Alzheimer's. Using digital twins, we could validate preliminary results on tau pathology biomarkers. If you are at the summit, check out the presentation by Yujia(Susanna) Qiao of Unlearn.AI tomorrow (Wednesday) at 2 pm.

Excited for AD/PD Boston! Our presentation, “Use of digital twins in a Phase 2a trial to predict disease progression of participants with mild-to-moderate Alzheimer’s supports early signals of efficacy,” created in collaboration with remynd, highlights how digital twins validated preliminary results on tau pathology biomarkers. This innovative approach provides valuable additional evidence supporting the advancement of the clinical program. ?? Session name: Enhancing the Landscape of Anti-Amyloids & Evaluating Combination Approaches ? Date/time: March 19 at 2 PM ET ??? Presenter: Yujia(Susanna) Qiao

?? Our Senior Director of Clinical Affairs, Luis Olmos, PhD, MBA, will be presenting at the Digital Innovations in Clinical Trials conference on March 20-21 in Berlin. His presentation, “Enhancing Clinical Trials with Digital Twins: Improving Design, Decision-Making, and Enrollment Speed” will offer expert insights into how #digitaltwins are being used to revolutionize #clinicaltrials. ——— TBM Group